Grennady Wirjanata

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5678262/grennady-wirjanata-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

1,053
citations

15
papers
h-index

32
g-index

33
ext. papers

1,281
ext. citations

9.7
avg, IF

L-index

#	Paper	IF	Citations
30	The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to parasite resistance. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	3
29	Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia. <i>International Journal for Parasitology: Drugs and Drug</i>	4	0
28	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia. <i>PLoS Neglected Tropical Diseases</i> , 2020 , 14, e0008295	4.8	5
27	Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome. <i>Nature Protocols</i> , 2020 , 15, 1881-1921	18.8	27
26	A comprehensive RNA handling and transcriptomics guide for high-throughput processing of Plasmodium blood-stage samples. <i>Malaria Journal</i> , 2020 , 19, 363	3.6	3
25	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia 2020 , 14, e0008295		
24	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia 2020 , 14, e0008295		
23	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia 2020 , 14, e0008295		
22	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia 2020 , 14, e0008295		
21	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia 2020 , 14, e0008295		
20	3,3VDisubstituted 5,5VBi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 2485-2498	8.3	10
19	Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	81
18	UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	25
17	Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	7
16	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. <i>Nature Communications</i> , 2017 , 8, 15159	17.4	44
15	Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017 , 97, 1788-1796	3.2	12
14	A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. <i>ACS Infectious Diseases</i> , 2016 , 2, 945-957	5.5	55

LIST OF PUBLICATIONS

13	Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms. <i>Malaria Journal</i> , 2016 , 15, 137	3.6	9
12	Expression of Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 361-7	5.9	20
11	Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia. <i>PLoS ONE</i> , 2016 , 11, e0165340	3.7	38
10	Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. <i>PLoS Medicine</i> , 2016 , 13, e1002138	11.6	24
9	A novel multiple-stage antimalarial agent that inhibits protein synthesis. <i>Nature</i> , 2015 , 522, 315-20	50.4	250
8	Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 6117-24	5.9	15
7	Contrasting ex vivo efficacies of "reversed chloroquine" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5721-6	5.9	11
6	Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry. <i>Malaria Journal</i> , 2015 , 14, 417	3.6	10
5	KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 5060-7	5.9	101
4	Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. <i>Nature Communications</i> , 2014 , 5, 5521	17.4	85
3	Quinolone-3-diarylethers: a new class of antimalarial drug. Science Translational Medicine, 2013, 5, 177r	a 37 .5	150
2	Effective preparation of Plasmodium vivax field isolates for high-throughput whole genome sequencing. <i>PLoS ONE</i> , 2013 , 8, e53160	3.7	24
1	Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5258-63	5.9	34